Egetis Therapeutics AB (publ) (LON:0ABW)

Market Cap	177.52M +57.6%
Revenue (ttm)	5.03M +35.4%
Net Income	-27.61M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	9.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,388
Average Volume	11,553
Open	5.66
Previous Close	5.63
Day's Range	5.66 - 5.69
52-Week Range	3.11 - 6.87
Beta	1.08
RSI	61.42
Earnings Date	Apr 29, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 42
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ABW

Financial Performance

In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.

Financial numbers in SEK